Real-world HIV clinical cases involving
drug-drug interactions

Have you managed a patient on an unboosted INSTI with an enzyme inducer?

We’re collecting real-world clinical cases to better understand drug interactions between unboosted integrase inhibitors (such as dolutegravir or bictegravir) and enzyme inducers (including rifampicin or carbamazepine).

Your experience could contribute to safer prescribing and help shape clinical practice.

Bictegravir – Rifabutin

Clinical implications of rifamycin-induced drug interactions in integrase inhibitor–based ART

This case highlights several key aspects: the clinical relevance of induction effects on integrase inhibitors, the limitations of unvalidated dose-adjustment strategies, and the value of therapeutic drug monitoring (TDM) in guiding individualized treatment decisions. Long-term follow-up, combined with close pharmacokinetic and virologic monitoring, will be essential to confirm the broader applicability of this approach in clinical practice.